Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Ipsen today announced that the phase III clinical trial evaluating Decapeptyl (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.

10 Feb 2014

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum for the treatment of frozen shoulder syndrome (adhesive capsulitis).

16 Dec 2013

Boston Scientific's Direxion Torqueable Microcatheter receives FDA clearance and CE Mark approval

Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation has received U.S. Food and Drug Administration clearance and CE Mark approval for its Direxion Torqueable Microcatheter.

20 Nov 2013

Findings shed light on the impact, treatment concerns related to uterine fibroids

Uterine fibroids cause significant fear and morbidity and can compromise workplace performance, according to a recently published survey of nearly 1,000 women in the U.S. The results were published this month in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.

24 Oct 2013

Uterine fibroids disproportionately impact African American women

A national survey has found that uterine fibroids have a disproportionate impact on African American women, causing more severe symptoms, interfering with their daily life, and causing them to miss work. These new findings are reported in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

10 Oct 2013

Researchers discover new procedure for treatment of uterine fibroids

Jersey Shore University Medical Center announces today that Mark Martens, M.D., chief of Obstetrics and Gynecology, performed the first Acessa procedure in New Jersey. The procedure is used for the treatment of uterine fibroids. Additionally, Jersey Shore's Jocelyn A. Carlo, M.D., Obstetrics/Gynecology, is performing the procedure.

1 Oct 2013

InSightec: First patient treated in ExAblate Neuro Phase III pivotal trial for tremor

InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.

11 Sep 2013

New research initiative to focus on ultrasound therapy

The Focused Ultrasound Foundation and Philips have entered into an innovative public-private collaboration with The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.

6 Sep 2013

Acessa Procedure: The Fibroid Treatment Collaborative's primary surgical therapy for uterine fibroids

The Fibroid Treatment Collaborative, with centers in Chicago, IL and Austin TX, announced today the adoption of the Acessa Procedure as its primary surgical therapy for patients suffering from uterine fibroids.

25 Jul 2013

AMA establishes new CPT code for RF Ablation of Uterine Fibroids

Halt Medical is very pleased to announce that the American Medical Association Current Procedure Terminology Panel has established a new CPT code specifically for Radiofrequency Ablation of Uterine Fibroids.

10 Jul 2013

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists.

3 Jun 2013

Non-invasive brain surgery: an interview with Dr Andres Lozano, University of Toronto

MR-guided focused ultrasound is a new technique that involves focusing 1024 beams of ultrasound through the skull to a focal point in the brain, very much like using the sun and a magnifying glass to burn a hole in a sheet of paper.

22 Apr 2013

Women with sufficient amounts of vitamin D less likely to develop uterine fibroids

Women who had sufficient amounts of vitamin D were 32 percent less likely to develop fibroids than women with insufficient vitamin D, according to a study from researchers at the National Institutes of Health.

16 Apr 2013

Halt Medical reveals initial commercialization results, additional launch plans for Acessa System

Halt Medical, Inc. announced today initial commercialization results for the Acessa System and additional launch plans.

1 Apr 2013

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.

27 Mar 2013

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2012.

9 Feb 2013

African-American women who reported childhood abuse had greater risk of uterine fibroids

According to a new study from the Slone Epidemiology Center (SEC) at Boston University, African-American women who reported sexual or physical abuse before age 11 had a greater risk of uterine fibroids in adulthood compared with women who had no such abuse history.

25 Jan 2013

Halt Medical receives $15M financing for commercialization of Acessa uterine fibroid treatment system

Halt Medical, Inc. announced today that it has received $15 million of financing to support commercialization of the Acessa System, a newly FDA cleared medical device to treat uterine fibroids.

2 Jan 2013

EC grants CE mark to InSightec’s ExAblate Neuro ultrasound system

InSightec Ltd. announced that its transcranial focused ultrasound system, ExAblate Neuro, has been awarded the European CE mark for the treatment of neurological disorders in the brain including essential tremor, Parkinson's disease and neuropathic pain.

4 Dec 2012

InSightec receives European CE mark for ExAblate Neuro system

Elbit Imaging Ltd. announced today that on December 3, 2012, Elbit Medical Technologies Ltd., announced that InSightec Ltd. has been awarded the European CE mark for its transcranial focused ultrasound system, ExAblate Neuro, with respect to the treatment of neurological disorders in the brain, including essential tremor, Parkinson's disease and neuropathic pain.

4 Dec 2012

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

Boston Scientific's Direxion Torqueable Microcatheter receives FDA clearance and CE Mark approval

Findings shed light on the impact, treatment concerns related to uterine fibroids

Uterine fibroids disproportionately impact African American women

Researchers discover new procedure for treatment of uterine fibroids

InSightec: First patient treated in ExAblate Neuro Phase III pivotal trial for tremor

New research initiative to focus on ultrasound therapy

Acessa Procedure: The Fibroid Treatment Collaborative's primary surgical therapy for uterine fibroids

AMA establishes new CPT code for RF Ablation of Uterine Fibroids

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Non-invasive brain surgery: an interview with Dr Andres Lozano, University of Toronto

Women with sufficient amounts of vitamin D less likely to develop uterine fibroids

Halt Medical reveals initial commercialization results, additional launch plans for Acessa System

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

African-American women who reported childhood abuse had greater risk of uterine fibroids

Halt Medical receives $15M financing for commercialization of Acessa uterine fibroid treatment system

EC grants CE mark to InSightec’s ExAblate Neuro ultrasound system

InSightec receives European CE mark for ExAblate Neuro system

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in